Drugs / PBCAR269A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04171843 | Apr 2020 → Oct 2022 | refractory plasma cell neoplasm | Precision BioSciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBCAR269A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04171843 ↗ |
| Modality | Cell therapy | “Allogeneic anti-BCMA CAR T-cell” NCT04171843 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of PBCAR269A” NCT04171843 ↗ |